Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Comprehensive substrate specificity profiling of the human Nek kinome reveals unexpected signaling outputs.

van de Kooij B, Creixell P, van Vlimmeren A, Joughin BA, Miller CJ, Haider N, Simpson CD, Linding R, Stambolic V, Turk BE, Yaffe MB.

Elife. 2019 May 24;8. pii: e44635. doi: 10.7554/eLife.44635.

2.

Association of Metabolic, Inflammatory, and Tumor Markers With Circulating Tumor Cells in Metastatic Breast Cancer.

Lohmann AE, Dowling RJO, Ennis M, Amir E, Elser C, Brezden-Masley C, Vandenberg T, Lee E, Fazaee K, Stambolic V, Goodwin PJ, Chang MC.

JNCI Cancer Spectr. 2018 Apr;2(2):pky028. doi: 10.1093/jncics/pky028. Epub 2018 Jul 12.

3.

β-Amyloid Precursor Protein Intracellular Domain Controls Mitochondrial Function by Modulating Phosphatase and Tensin Homolog-Induced Kinase 1 Transcription in Cells and in Alzheimer Mice Models.

Goiran T, Duplan E, Chami M, Bourgeois A, El Manaa W, Rouland L, Dunys J, Lauritzen I, You H, Stambolic V, Biféri MG, Barkats M, Pimplikar SW, Sergeant N, Colin M, Morais VA, Pardossi-Piquard R, Checler F, Alves da Costa C.

Biol Psychiatry. 2018 Mar 1;83(5):416-427. doi: 10.1016/j.biopsych.2017.04.011. Epub 2017 May 3.

4.

Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32.

Lohmann AE, Liebman MF, Brien W, Parulekar WR, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, Rastogi P, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Pritchard KI, Whelan TJ, Mukherjee SD, Chalchal HI, Bernstein V, Stambolic V, Chen BE, Goodwin PJ; From the CCTG, Alliance, SWOG, ECOG, NSABP Cooperative Groups.

Breast Cancer Res Treat. 2017 Jul;164(2):371-378. doi: 10.1007/s10549-017-4265-x. Epub 2017 Apr 26.

5.

Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2.

Ren Z, Aerts JL, Vandenplas H, Wang JA, Gorbenko O, Chen JP, Giron P, Heirman C, Goyvaerts C, Zacksenhaus E, Minden MD, Stambolic V, Breckpot K, De Grève J.

Cell Death Dis. 2016 Dec 22;7(12):e2560. doi: 10.1038/cddis.2016.430.

6.

Association of Obesity-Related Metabolic Disruptions With Cancer Risk and Outcome.

Lohmann AE, Goodwin PJ, Chlebowski RT, Pan K, Stambolic V, Dowling RJ.

J Clin Oncol. 2016 Dec 10;34(35):4249-4255. Epub 2016 Nov 7. Review.

PMID:
27903146
7.

Regulation of the protein kinase activity of ShaggyZeste-white3 by components of the Wingless pathway in Drosophila cells and embryos.

Ruel L, Stambolic V, Ali A, Manoukian AS, Woodgett JR.

J Biol Chem. 2016 Oct 28;291(44):23364. No abstract available.

8.

Preface.

Salmena L, Stambolic V.

Methods Mol Biol. 2016;1388:v. No abstract available.

PMID:
27482589
9.

Metformin Pharmacokinetics in Mouse Tumors: Implications for Human Therapy.

Dowling RJ, Lam S, Bassi C, Mouaaz S, Aman A, Kiyota T, Al-Awar R, Goodwin PJ, Stambolic V.

Cell Metab. 2016 Apr 12;23(4):567-8. doi: 10.1016/j.cmet.2016.03.006. No abstract available.

10.

mTORC1 and CK2 coordinate ternary and eIF4F complex assembly.

Gandin V, Masvidal L, Cargnello M, Gyenis L, McLaughlan S, Cai Y, Tenkerian C, Morita M, Balanathan P, Jean-Jean O, Stambolic V, Trost M, Furic L, Larose L, Koromilas AE, Asano K, Litchfield D, Larsson O, Topisirovic I.

Nat Commun. 2016 Apr 4;7:11127. doi: 10.1038/ncomms11127.

11.

PTEN at 18: Still Growing.

Gorbenko O, Stambolic V.

Methods Mol Biol. 2016;1388:13-9. doi: 10.1007/978-1-4939-3299-3_2.

PMID:
27033067
12.

The Rho Guanine Nucleotide Exchange Factor DRhoGEF2 Is a Genetic Modifier of the PI3K Pathway in Drosophila.

Chang YJ, Zhou L, Binari R, Manoukian A, Mak T, McNeill H, Stambolic V.

PLoS One. 2016 Mar 25;11(3):e0152259. doi: 10.1371/journal.pone.0152259. eCollection 2016.

13.

The acetyltransferase Tip60 contributes to mammary tumorigenesis by modulating DNA repair.

Bassi C, Li YT, Khu K, Mateo F, Baniasadi PS, Elia A, Mason J, Stambolic V, Pujana MA, Mak TW, Gorrini C.

Cell Death Differ. 2016 Jul;23(7):1198-208. doi: 10.1038/cdd.2015.173. Epub 2016 Feb 26.

14.

Obesity and cancer, a case for insulin signaling.

Poloz Y, Stambolic V.

Cell Death Dis. 2015 Dec 31;6:e2037. doi: 10.1038/cddis.2015.381. Review.

15.

The Rho-guanine nucleotide exchange factor PDZ-RhoGEF governs susceptibility to diet-induced obesity and type 2 diabetes.

Chang YJ, Pownall S, Jensen TE, Mouaaz S, Foltz W, Zhou L, Liadis N, Woo M, Hao Z, Dutt P, Bilan PJ, Klip A, Mak T, Stambolic V.

Elife. 2015 Oct 29;4. pii: e06011. doi: 10.7554/eLife.06011.

16.

Cancer: Precise control of localized signals.

Stambolic V.

Nature. 2015 Jun 4;522(7554):38-40. doi: 10.1038/nature14531. Epub 2015 May 27. No abstract available.

PMID:
26017306
17.

Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study.

Dowling RJ, Niraula S, Chang MC, Done SJ, Ennis M, McCready DR, Leong WL, Escallon JM, Reedijk M, Goodwin PJ, Stambolic V.

Breast Cancer Res. 2015 Mar 3;17:32. doi: 10.1186/s13058-015-0540-0.

18.

Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32.

Goodwin PJ, Parulekar WR, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, Rastogi P, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Pritchard KI, Whelan TJ, Mukherjee SD, Chalchal HI, Oja CD, Tonkin KS, Bernstein V, Chen BE, Stambolic V.

J Natl Cancer Inst. 2015 Mar 4;107(3). pii: djv006. doi: 10.1093/jnci/djv006. Print 2015 Mar.

19.

Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial.

Hadad SM, Coates P, Jordan LB, Dowling RJ, Chang MC, Done SJ, Purdie CA, Goodwin PJ, Stambolic V, Moulder-Thompson S, Thompson AM.

Breast Cancer Res Treat. 2015 Feb;150(1):149-55. doi: 10.1007/s10549-015-3307-5. Epub 2015 Feb 15.

PMID:
25682077
20.

Characterization of nuclear PTEN and its post translational modifications.

Ho J, Bassi C, Stambolic V.

Methods. 2015 May;77-78:104-11. doi: 10.1016/j.ymeth.2015.01.006. Epub 2015 Jan 20. Review.

PMID:
25616216
21.

Impact of the obesity epidemic on cancer.

Goodwin PJ, Stambolic V.

Annu Rev Med. 2015;66:281-96. doi: 10.1146/annurev-med-051613-012328. Epub 2014 Nov 12. Review.

PMID:
25423596
22.

A unified nomenclature and amino acid numbering for human PTEN.

Pulido R, Baker SJ, Barata JT, Carracedo A, Cid VJ, Chin-Sang ID, Davé V, den Hertog J, Devreotes P, Eickholt BJ, Eng C, Furnari FB, Georgescu MM, Gericke A, Hopkins B, Jiang X, Lee SR, Lösche M, Malaney P, Matias-Guiu X, Molina M, Pandolfi PP, Parsons R, Pinton P, Rivas C, Rocha RM, Rodríguez MS, Ross AH, Serrano M, Stambolic V, Stiles B, Suzuki A, Tan SS, Tonks NK, Trotman LC, Wolff N, Woscholski R, Wu H, Leslie NR.

Sci Signal. 2014 Jul 1;7(332):pe15. doi: 10.1126/scisignal.2005560.

23.

Structure-guided mutation of the conserved G3-box glycine in Rheb generates a constitutively activated regulator of mammalian target of rapamycin (mTOR).

Mazhab-Jafari MT, Marshall CB, Ho J, Ishiyama N, Stambolic V, Ikura M.

J Biol Chem. 2014 May 2;289(18):12195-201. doi: 10.1074/jbc.C113.543736. Epub 2014 Mar 19.

24.

Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway.

Gorrini C, Gang BP, Bassi C, Wakeham A, Baniasadi SP, Hao Z, Li WY, Cescon DW, Li YT, Molyneux S, Penrod N, Lupien M, Schmidt EE, Stambolic V, Gauthier ML, Mak TW.

Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4472-7. doi: 10.1073/pnas.1324136111. Epub 2014 Feb 24.

25.

PTEN, here, there, everywhere.

Bassi C, Stambolic V.

Cell Death Differ. 2013 Dec;20(12):1595-6. doi: 10.1038/cdd.2013.127. No abstract available.

26.

Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress.

Bassi C, Ho J, Srikumar T, Dowling RJ, Gorrini C, Miller SJ, Mak TW, Neel BG, Raught B, Stambolic V.

Science. 2013 Jul 26;341(6144):395-9. doi: 10.1126/science.1236188. Erratum in: Science. 2013 Sep 6;341(6150):1064.

27.

Membrane-dependent modulation of the mTOR activator Rheb: NMR observations of a GTPase tethered to a lipid-bilayer nanodisc.

Mazhab-Jafari MT, Marshall CB, Stathopulos PB, Kobashigawa Y, Stambolic V, Kay LE, Inagaki F, Ikura M.

J Am Chem Soc. 2013 Mar 6;135(9):3367-70. doi: 10.1021/ja312508w. Epub 2013 Feb 20.

PMID:
23409921
28.

Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study.

Niraula S, Dowling RJ, Ennis M, Chang MC, Done SJ, Hood N, Escallon J, Leong WL, McCready DR, Reedijk M, Stambolic V, Goodwin PJ.

Breast Cancer Res Treat. 2012 Oct;135(3):821-30. doi: 10.1007/s10549-012-2223-1. Epub 2012 Aug 30.

PMID:
22933030
29.

An autoinhibited noncanonical mechanism of GTP hydrolysis by Rheb maintains mTORC1 homeostasis.

Mazhab-Jafari MT, Marshall CB, Ishiyama N, Ho J, Di Palma V, Stambolic V, Ikura M.

Structure. 2012 Sep 5;20(9):1528-39. doi: 10.1016/j.str.2012.06.013. Epub 2012 Jul 19.

30.

Probing the GTPase cycle with real-time NMR: GAP and GEF activities in cell extracts.

Marshall CB, Meiri D, Smith MJ, Mazhab-Jafari MT, Gasmi-Seabrook GM, Rottapel R, Stambolic V, Ikura M.

Methods. 2012 Aug;57(4):473-85. doi: 10.1016/j.ymeth.2012.06.014. Epub 2012 Jun 28.

PMID:
22750304
31.

Diabetes, metformin, and breast cancer: lilac time?

Goodwin PJ, Thompson AM, Stambolic V.

J Clin Oncol. 2012 Aug 10;30(23):2812-4. doi: 10.1200/JCO.2012.42.3319. Epub 2012 Jun 11. No abstract available.

PMID:
22689806
32.

Metformin in cancer: translational challenges.

Dowling RJ, Niraula S, Stambolic V, Goodwin PJ.

J Mol Endocrinol. 2012 Mar 29;48(3):R31-43. doi: 10.1530/JME-12-0007. Print 2012 Jun. Review.

PMID:
22355097
33.

Nek family of kinases in cell cycle, checkpoint control and cancer.

Moniz L, Dutt P, Haider N, Stambolic V.

Cell Div. 2011 Oct 31;6:18. doi: 10.1186/1747-1028-6-18.

34.

Obesity and insulin resistance in breast cancer--chemoprevention strategies with a focus on metformin.

Goodwin PJ, Stambolic V.

Breast. 2011 Oct;20 Suppl 3:S31-5. doi: 10.1016/S0960-9776(11)70291-0. Review. Erratum in: Breast. 2012 Apr;21(2):224.

PMID:
22015290
35.

Understanding the benefit of metformin use in cancer treatment.

Dowling RJ, Goodwin PJ, Stambolic V.

BMC Med. 2011 Apr 6;9:33. doi: 10.1186/1741-7015-9-33. Review.

36.

Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents.

Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, Hershman DL, Hobday TJ, Ligibel JA, Mayer IA, Pritchard KI, Whelan TJ, Rastogi P, Shepherd LE.

Breast Cancer Res Treat. 2011 Feb;126(1):215-20. doi: 10.1007/s10549-010-1224-1. Epub 2010 Oct 26. Review.

PMID:
20976543
37.

Nek10 mediates G2/M cell cycle arrest and MEK autoactivation in response to UV irradiation.

Moniz LS, Stambolic V.

Mol Cell Biol. 2011 Jan;31(1):30-42. doi: 10.1128/MCB.00648-10. Epub 2010 Oct 18.

38.

Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice.

Molyneux SD, Di Grappa MA, Beristain AG, McKee TD, Wai DH, Paderova J, Kashyap M, Hu P, Maiuri T, Narala SR, Stambolic V, Squire J, Penninger J, Sanchez O, Triche TJ, Wood GA, Kirschner LS, Khokha R.

J Clin Invest. 2010 Sep;120(9):3310-25. doi: 10.1172/JCI42391. Epub 2010 Aug 9.

39.

Regulation of adipocyte differentiation by distinct subcellular pools of protein kinase B (PKB/Akt).

Maiuri T, Ho J, Stambolic V.

J Biol Chem. 2010 May 14;285(20):15038-47. doi: 10.1074/jbc.M110.121434. Epub 2010 Mar 11.

40.

Real-time NMR study of guanine nucleotide exchange and activation of RhoA by PDZ-RhoGEF.

Gasmi-Seabrook GM, Marshall CB, Cheung M, Kim B, Wang F, Jang YJ, Mak TW, Stambolic V, Ikura M.

J Biol Chem. 2010 Feb 19;285(8):5137-45. doi: 10.1074/jbc.M109.064691. Epub 2009 Dec 17.

41.

Real-time NMR study of three small GTPases reveals that fluorescent 2'(3')-O-(N-methylanthraniloyl)-tagged nucleotides alter hydrolysis and exchange kinetics.

Mazhab-Jafari MT, Marshall CB, Smith M, Gasmi-Seabrook GM, Stambolic V, Rottapel R, Neel BG, Ikura M.

J Biol Chem. 2010 Feb 19;285(8):5132-6. doi: 10.1074/jbc.C109.064766. Epub 2009 Dec 14.

42.

Metformin in breast cancer: time for action.

Goodwin PJ, Ligibel JA, Stambolic V.

J Clin Oncol. 2009 Jul 10;27(20):3271-3. doi: 10.1200/JCO.2009.22.1630. Epub 2009 Jun 1. No abstract available.

PMID:
19487373
43.

Characterization of the intrinsic and TSC2-GAP-regulated GTPase activity of Rheb by real-time NMR.

Marshall CB, Ho J, Buerger C, Plevin MJ, Li GY, Li Z, Ikura M, Stambolic V.

Sci Signal. 2009 Jan 27;2(55):ra3. doi: 10.1126/scisignal.2000029.

44.

The ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability and localization.

Fouladkou F, Landry T, Kawabe H, Neeb A, Lu C, Brose N, Stambolic V, Rotin D.

Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8585-90. doi: 10.1073/pnas.0803233105. Epub 2008 Jun 18.

45.

Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?

Stambolic V, Woodgett JR, Fantus IG, Pritchard KI, Goodwin PJ.

Breast Cancer Res Treat. 2009 Mar;114(2):387-9. doi: 10.1007/s10549-008-0015-4. Epub 2008 Apr 26. Review. No abstract available.

PMID:
18438706
46.

Functional distinctions of protein kinase B/Akt isoforms defined by their influence on cell migration.

Stambolic V, Woodgett JR.

Trends Cell Biol. 2006 Sep;16(9):461-6. Epub 2006 Jul 25. Review.

PMID:
16870447
47.

Localization of Rheb to the endomembrane is critical for its signaling function.

Buerger C, DeVries B, Stambolic V.

Biochem Biophys Res Commun. 2006 Jun 9;344(3):869-80. Epub 2006 Apr 19.

PMID:
16631613
48.

Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10).

White ES, Atrasz RG, Hu B, Phan SH, Stambolic V, Mak TW, Hogaboam CM, Flaherty KR, Martinez FJ, Kontos CD, Toews GB.

Am J Respir Crit Care Med. 2006 Jan 1;173(1):112-21. Epub 2005 Sep 22.

49.

Prostaglandin E(2) inhibits fibroblast migration by E-prostanoid 2 receptor-mediated increase in PTEN activity.

White ES, Atrasz RG, Dickie EG, Aronoff DM, Stambolic V, Mak TW, Moore BB, Peters-Golden M.

Am J Respir Cell Mol Biol. 2005 Feb;32(2):135-41. Epub 2004 Nov 11. Erratum in: Am J Respir Cell Mol Biol. 2008 Aug;39(2):252.

50.

grb2 heterozygosity rescues embryonic lethality but not tumorigenesis in pten+/- mice.

Cully M, Elia A, Ong SH, Stambolic V, Pawson T, Tsao MS, Mak TW.

Proc Natl Acad Sci U S A. 2004 Oct 26;101(43):15358-63. Epub 2004 Oct 18.

Supplemental Content

Loading ...
Support Center